Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

The website for the popular JDownloader download manager was compromised earlier this week to distribute malicious Windows and Linux installers, with the Windows payload found deploying a Python-based ...

In July 2025, REPL announced it had received a CRL for its biologics license application (BLA) for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma patients who were PD-1 ...

Neutral-atom arrays are a rapidly emerging platform to create quantum computers. In a foundational study led by graduate students Aaron Holman and Yuan Xu from the Will and Yu labs, respectively, the ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

Fintel reports that on October 20, 2025, JP Morgan upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underweight to Neutral. As of September 30, 2025, the average one-year price target ...

The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject of discussion was Replimune's RP1, a cancer drug being trialed as a ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...

On June 11, 2025, the Python core team released Python 3.13.5, the fifth maintenance update to the 3.13 line. This release is not about flashy new language features, instead, it addresses some ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Here are the most important concepts developers must know when they size Java arrays and deal ...